ATYR at a glance
aTYR PHARMA INC (ATYR, SEC CIK 1339970) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on September 24, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), aTYR PHARMA INC (ATYR) reported revenue of $190,000 (down 19.1% from FY2024) and a net loss of $74.1 million. Diluted EPS was -$0.80.
- As of June 30, 2026, 19 institutional investment managers tracked by SignalX reported holding aTYR PHARMA INC (ATYR) shares worth $10.3 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by SCHIMMEL PAUL on May 27, 2026 of 100,000 shares at $0.50 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $190K
- −19.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 19 funds
- $10.3M · −5 vs prior quarter
- Latest 8-K
- Sep 24, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New capital risk triggered by planned Phase 3 efzofitimod study and August restructuring reducing workforce approximately 60% to 20 employees
- Regulatory approval risk after FDA deemed EFZO-FIT failed and raised safety concerns over higher dose and narrower patient population
- Clinical execution risk from planned dosing increase to 5.0 mg/kg every three weeks versus every four weeks previously
- Liquidity risk with $58.9 million in cash, restricted cash and available-for-sale investments as of June 30, 2026
- Financial sustainability risk with $21.1 million six-month net loss and $627.3 million accumulated deficit
AI summary of the ATYR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- FDA alignment on Phase 3 efzofitimod protocol reduces regulatory uncertainty ahead of U.S. and European submissions
- Global trial targets approximately 372 patients over 54 weeks, testing 5.0 mg/kg versus placebo every 3 weeks
Item 2.02: Results of Operations and Financial Condition
- Quarterly financial results cover the period ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the detailed results
Item EX-99.1: Item EX-99.1
- Q2 2026 revenue-free biotech reported net loss $10.3M, or $0.11 per share, versus $19.5M, or $0.22, in Q2 2025
- Cash and investments fell to $58.9M from $80.9M at December 31, 2025, funding operations into late 2028 under current plans
Item 1.02: Termination of a Material Definitive Agreement
- Kyorin collaboration terminated July 30, 2026, ahead of the previously expected 90-day termination timeline
- Efzofitimod development and commercialization rights in Japan reverted to aTyr
Item EX-99.1: Item EX-99.1
- Kyorin collaboration terminated July 30, 2026, ending the 2020 license partnership and dissolving the joint steering committee
- aTyr regains perpetual, royalty-free worldwide rights to efzofitimod, including exclusive rights to New Kyorin IP and New Joint IP
AI summaries of ATYR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ATYR
Don't miss the next ATYR filing
- Alerts as it files. A push when ATYR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ATYR, by share count.
- Ask anything. An AI agent that reads every ATYR filing and answers with sources.
ATYR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Yaras Brandon | A | Oct 1, 2026 | 410,000 | - |
| SCHIMMEL PAUL | Buy | May 27, 2026 | 100,000 | $0.50 |
| Zaknoen Sara | A | May 11, 2026 | 50,000 | - |
| Gross Jane A | A | May 11, 2026 | 50,000 | - |
| BENEVICH ERIC | A | May 11, 2026 | 50,000 | - |
| SCHIMMEL PAUL | A | May 11, 2026 | 50,000 | - |
| Gross Jane A | A | May 11, 2026 | 50,000 | - |
| Coughlin Timothy | A | May 11, 2026 | 50,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $353K | $235K | $190K |
| Operating Income | - | -$67.9M | -$77.6M |
| Net Income | -$50.4M | -$64.0M | -$74.1M |
| Op. Margin | - | -28899.6% | -40856.3% |
| Net Margin | -14274.5% | -27243.8% | -39009.5% |
| Balance Sheet | |||
| Total Assets | - | $96.8M | $93.0M |
| Equity | $90.7M | $70.0M | $67.5M |
| ROE | -55.6% | -91.4% | -109.8% |
| Per Share | |||
| EPS | $-0.94 | $-0.86 | $-0.80 |
| Cash Flow | |||
| Operating CF | - | -$69.1M | -$62.0M |
| CapEx | - | $65K | $77K |
Source: XBRL data in aTYR PHARMA INC (ATYR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ATYR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 19 | $10.3M |
| Q1 2026 | 24 | $26.3M |
| Q4 2025 | 20 | $25.6M |
| Q3 2025 | 23 | $26.8M |
| Q2 2025 | 22 | $152.9M |
| Q1 2025 | 14 | $64.3M |
| Q4 2024 | 11 | $63.6M |
| Q3 2024 | 8 | $4.8M |
- AQR Capital Management+2.11M (+426%)
- Citadel Advisors LLC+1.19M (+2522%)
- Goldman Sachs Group+358.0K (+126%)
- Renaissance Technologies LLC+124.7K (+308%)
- Morgan Stanley+118.2K (+10%)
- FMR LLC (Fidelity)−12.24M (-83%)
- BlackRock−4.62M (-72%)
- State Street Corp−1.26M (-72%)
- Millennium Management−985.2K (-60%)
- Northern Trust−491.0K (-69%)
- Vanguard Portfolio Management LLC−569.2K
- BNY Mellon−193.5K
- Invesco Ltd−46.4K
- T. Rowe Price Group−46.1K
- Prudential Financial−14.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 141 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ATYR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 1, 2026 | - | - | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 31, 2026 | - | Analysis | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 10-Q | May 15, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 15, 2026 | - | Analysis | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-K | Mar 5, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 5, 2026 | - | Analysis | - |
| 4 | Feb 4, 2026 | - | - | |
| 4 | Feb 4, 2026 | - | - | |
| 4 | Feb 4, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 8-K | Dec 5, 2025 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
ATYR SEC filings: frequently asked questions
Which institutions hold ATYR stock?
As of June 30, 2026, the largest aTYR PHARMA INC (ATYR) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($2.3 million), AQR Capital Management ($1.6 million), FMR LLC (Fidelity) ($1.5 million), BlackRock ($1.1 million), Morgan Stanley ($801,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ATYR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), aTYR PHARMA INC (ATYR) reported revenue of $190,000 (down 19.1% from FY2024) and a net loss of $74.1 million. Diluted EPS was -$0.80. The figures come from the XBRL data in the 10-K.
What did ATYR report in its latest 8-K?
aTYR PHARMA INC (ATYR) filed an 8-K on September 24, 2026 reporting Item 8.01 (Other Events). FDA alignment on Phase 3 efzofitimod protocol reduces regulatory uncertainty ahead of U.S. and European submissions.
What are the latest ATYR SEC filings?
aTYR PHARMA INC (ATYR) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on September 24, 2026 and a Form 4 insider filing on October 1, 2026.
What is ATYR's SEC CIK number?
aTYR PHARMA INC (ATYR)'s SEC Central Index Key (CIK) is 1339970. EDGAR lists every ATYR filing under that number.
Ask anything about ATYR
The research agent reads ATYR's filings, financials, insider trades and 13F holders, then answers with sources.